Amundi Buys 846,909 Shares of Zoetis Inc. $ZTS

Key Points

• Amundi has increased its stake in Zoetis Inc. by 30.8% to hold 3,595,628 shares valued at approximately $575.69 million, representing about 0.81% of the company.
• Several hedge funds have altered their positions in Zoetis during the first quarter, with over 92% of the stock now owned by institutional investors and hedge funds.
• Zoetis reported strong quarterly earnings with an EPS of $1.76, exceeding analysts' expectations, and forecasts a FY 2025 EPS range between 6.300 and 6.400.

Amundi raised its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 30.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,595,628 shares of the company's stock after purchasing an additional 846,909 shares during the period. Amundi owned 0.81% of Zoetis worth $575,691,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of ZTS. Brighton Jones LLC increased its holdings in shares of Zoetis by 180.4% in the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company's stock valued at $754,000 after purchasing an additional 2,978 shares during the last quarter. Schonfeld Strategic Advisors LLC acquired a new position in shares of Zoetis in the fourth quarter valued at about $308,000. Aptus Capital Advisors LLC grew its stake in shares of Zoetis by 46.6% in the fourth quarter. Aptus Capital Advisors LLC now owns 6,643 shares of the company's stock valued at $1,082,000 after acquiring an additional 2,111 shares in the last quarter. Captrust Financial Advisors grew its stake in shares of Zoetis by 23.0% in the fourth quarter. Captrust Financial Advisors now owns 98,701 shares of the company's stock valued at $16,081,000 after acquiring an additional 18,476 shares in the last quarter. Finally, Bridgefront Capital LLC acquired a new position in shares of Zoetis in the fourth quarter valued at about $785,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ZTS. Stifel Nicolaus downgraded shares of Zoetis from a "buy" rating to a "hold" rating and decreased their price target for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Leerink Partnrs downgraded shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Piper Sandler upped their price target on shares of Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a research note on Monday, August 11th. Finally, Leerink Partners downgraded shares of Zoetis from an "outperform" rating to a "market perform" rating and decreased their price target for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Four analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $202.43.

Zoetis Price Performance

Zoetis stock traded down $0.05 during trading hours on Friday, reaching $153.15. 1,895,936 shares of the stock were exchanged, compared to its average volume of 2,304,532. The company has a market cap of $67.87 billion, a P/E ratio of 26.36, a price-to-earnings-growth ratio of 2.46 and a beta of 0.89. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33. The stock has a 50 day moving average of $153.16 and a two-hundred day moving average of $157.72.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. The firm had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business's revenue for the quarter was up 4.2% on a year-over-year basis. During the same period in the prior year, the company posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.